Melius MicroBiomics, a biotech company, specializes in modulating the microbiome and gut health through the integration of microbiology and bioengineering. This integration is aimed at creating a balanced microbiome using its patented Genetically Engineered Microbial Medicine (GEMM). GEMMs™ represent a sophisticated approach to microbiome-based therapy, utilizing the natural healing properties of beneficial microbes. This is further enhanced by the addition of genes that improve their survival and establishment in hosts, including humans and animals.
The problem with probiotics lies in their limitations when facing an inflamed gut, where they often become non-viable. Despite their potential health benefits, probiotics frequently lack clinical efficacy, partly due to their susceptibility to inflammation and oxidative stress. Additionally, there's a noticeable deficiency in guidelines, clinical data, and substantiated claims regarding their use. This issue is compounded by low regulatory standards and the low variability rates found in standard formulations, raising concerns about their effectiveness and reliability.
LICENSING AGREEMENT WITH
MMB and UBC have entered an option agreement to license and commercialize the patented and patent-pending technology relating to a designer live biotherapeutics for IBD therapy.
This technology is designed to improve the overall health and well-being of the user by promoting the growth of beneficial bacteria in the gut.
Pre-clinical trial results have been overwhelmingly positive, with the biotic demonstrating a high level of safety and effectiveness in improving gut health. We plan to conduct a series of clinical trials to further evaluate live biotherapeutics in humans.